Daré Bioscience reports Q3 2023 cash of $13.8M; XACIATO milestone triggered

Dare Bioscience, Inc.

2023-Q3 EPS reported -$0.29 revenue$1,000,000

Cash and equivalents $13.8M at September 30, 2023; evaluating financing options.
R&D expenses increased to $6.7M in Q3 2023 from $4.5M in Q3 2022, driven by Sildenafil Cream and Ovaprene activities.
G&A expenses unchanged at $2.7M; focus on efficient operations.
Received $1.8M first commercial milestone payment from Organon for XACIATO US launch.
On track to start Ovaprene Phase 3 enrollment in Q4 2023 and end-of-Phase 2 meeting for Sildenafil Cream with FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.